Table 2.
Biochemical and hematic parameters according to the groups studied.
| Parameters | Healthy (n = 11) | NAFLD-placebo (n = 11) | NAFLD-MO ethanolic extract (n = 11) | NAFLD-MO infusion (n = 11) | p ANOVA | |
|---|---|---|---|---|---|---|
| Biochemical | Cholesterol (mg/dL) | 116.9 ± 12.0 | 181.2 ± 15.0a | 120.1 ± 11.8d | 104.3 ± 11.4e | <0.001 |
| Triglycerides (mg/dL) | 114.8 ± 15.5 | 185.5 ± 12.6a | 116.6 ± 15.7d | 93.8 ± 11.2ef | <0.001 | |
| Total lipids (mg/dL) | 156.1 ± 9.6 | 299.8 ± 15.1a | 199.3 ± 14.1d | 184.3 ± 13.0e | <0.001 | |
| SGOT (U/L) | 184.0 ± 14.2 | 403.0 ± 12.1a | 210.1 ± 14.3d | 178.1 ± 15.0ef | <0.001 | |
| SGPT (U/L) | 128.9 ± 11.9 | 241.6 ± 16.3a | 130.8 ± 13.9d | 113.2 ± 7.0ef | <0.001 | |
| Blood glucose (mg/dL) | 88.9 ± 13.8 | 141.1 ± 20.9a | 109.0 ± 9.2d | 114.1 ± 14.8e | 0.002 | |
| Urea (mg/dL) | 11.9 ± 5.3 | 15.4 ± 5.8 | 12.8 ± 2.8 | 11.7 ± 5.1 | 0.525 | |
|
| ||||||
| Hematic | Hemoglobin (g/dL) | 12.5 ± 1.1 | 14.3 ± 0.5a | 14.18 ± 0.2 | 14.2 ± 0.7c | <0.001 |
| Hematocrit (%) | 35.6 ± 4.1 | 39.7 ± 1.5 | 37.77 ± 0.1 | 40.0 ± 0.74 | 0.902 | |
| Platelets (10∧3/μL) | 1207.2 ± 38.1 | 1210.8 ± 48.8 | 1008.7 ± 54.1 | 1127.1 ± 31.5 | 0.575 | |
| Leukocytes (10∧9/μL | 6.4 ± 2.0 | 6.4 ± 2.1 | 6.4 ± 1.6 | 6.45 ± 0.6 | 0.262 | |
| Erythrocytes (10∧12/μL) | 8.1 ± 1.0 | 7.7 ± 0.9 | 7.6 ± 0.2 | 7.80 ± 0.3 | 0.675 | |
All values are expressed as mean ± SEM; the differences of Tukey's post hoc analysis are marked when they are significant: ap < 0.05, healthy vs. NAFLD-placebo, bp < 0.05, healthy vs. NAFLD-MO ethanolic extract, cp < 0.05, healthy vs. NAFLD-MO infusion, dp < 0.05, NAFLD-placebo vs. NAFLD-MO ethanolic extract, ep < 0.05, NAFLD-placebo vs. NAFLD-MO infusion, and fp < 0.05, NAFLD-MO ethanolic extract vs. NAFLD-MO infusion (n = 11 per group).